ICAM-1 overexpression counteracts immune-suppress cell-derived PGE2 to restore CTL function by Basingab, Fatemah & Morgan, David
                          Basingab, F., & Morgan, D. (2018). ICAM-1 overexpression counteracts
immune-suppress cell-derived PGE2 to restore CTL function. Journal of
Immunological Sciences, 2(1), 37-45.
Publisher's PDF, also known as Version of record
License (if available):
CC BY
Link to publication record in Explore Bristol Research
PDF-document
University of Bristol - Explore Bristol Research
General rights
This document is made available in accordance with publisher policies. Please cite only the published
version using the reference above. Full terms of use are available:
http://www.bristol.ac.uk/pure/about/ebr-terms
Basingab FS, Morgan DJ. J Immunological Sci. (2018); 2(1): 37-45
Journal of Immunological Sciences
Research Article Open Access
Page 37 of 45
ICAM-1 overexpression counteracts immune-suppression by tumour 
cell-derived PGE2 to restore CTL function
Fatemah Salem Basingab1,2 and David John Morgan1*
1Department of Cellular and Molecular Medicine, University of Bristol, School of Biomedical Sciences, University Walk, Bristol BS8 1TD, UK
2Department of Biology, Faculty of Science, King Abdulaziz University, PO Box 80203, Jeddah 21589, Kingdom of Saudi Arabia
Article Info
Article Notes 
Received: January 04, 2018 
Accepted: February 05, 2018
*Correspondence: 
Dr. David John Morgan, Department of Cellular and 
Molecular Medicine, University of Bristol, School of 
Biomedical Sciences, University Walk, Bristol BS8 1TD, UK; 
E-mail: D.J.Morgan@bristol.ac.uk  
© 2018 Morgan DJ. This article is distributed under the terms of 
the Creative Commons Attribution 4.0 International License.
Keywords
Prostaglandin-E2 (PGE2)
Tumour microenvironment (TME)
Cytotoxic T Lymphocyte (CTL)
Intercellular adhesion molecule-1 (ICAM-1) Cyclooxygenase 
(COX-2)
  
ABSTRACT
Tumour-infiltrating cytotoxic T lymphocytes (CTLs) play a key role in 
tumour killing.  However, many cancers adopt various strategies to induce 
immunosuppression. Priming of naïve CD8+ T cells to become CTLs occurs via 
cognate interactions of the T cell receptor (TcR) and CD28 with tumour-derived 
peptide epitopes expressed on major histocompatibility complex (MHC) class 
I molecules and CD80/CD86 on T cells and antigen-presenting cells (APCs) 
respectively. Here we report that, in the absence of CD80/CD86 expression by 
renal carcinoma (Renca) cells, expression of intercellular adhesion molecule-1 
(ICAM-1) by Renca cells provides a potent alternative co-stimulation to a 
tumour-specific CD8+ T cells causing them to produce interferon gamma (IFN-γ) 
which is crucial for the further up-regulation of ICAM-1 on tumour cells. We 
have shown that overexpression of cyclooxygenase-2 (COX-2), by Renca cells 
(Renca-T3), results in increased levels of prostaglandin (PG) E
2 
production, 
which can directly suppress anti-tumour CD8+ T cells resulting in loss of CTL 
function in vivo and cause metastases to the tumor-draining lymph nodes 
(TDLNs). Significantly, our data also show that overexpression of ICAM-1 on 
Renca-T3 cells can counteract the immune-suppressive effect of PGE
2
 and 
restore CTL responses. 
IntroductionAnti-tumour CD8+ cytotoxic T lymphocytes (CTLs) are capable 
of producing interferon gamma (IFN-γ) and cytolytic enzymes and are crucial for cancer regression1. Priming naïve CD8+ T cells 
to become CTLs requires two signals; the first comes from T cell receptor (TcR) interaction with peptide epitope presented by major histocompatibility complex (MHC-I) molecules on antigen-presenting cells (APCs). The second signal was long thought to be solely provided by the interaction of T cell-expressed CD28 with the classical co-stimulatory CD80/CD86 molecules on APCs. However, CD80- and CD86-mediated co-stimulation is not provided by most tumour cells. Thus, the direct interaction between naïve CD8+ T cells and tumour cells often leads to tolerance induction. In the absence of CD80/CD862, intercellular adhesion molecule-1 (ICAM-1) interaction with lymphocyte function associated antigen-1 (LFA-1), expressed by T cells, can provide a co-stimulatory signal resulting in the formation of CTLs3,4. ICAM-1 is a member of immunoglobulin superfamily expressed by many cells including various tumour cells5. The main role of ICAM-
1 is to firmly arrest leukocytes and facilitate extravasation through 
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the blood vessels to sites of inflammation. However, ICAM-1 also enables T cells to adhere to other cells including APC, endothelial cells, and to normal and tumour cells6. In some cancer patients elevated levels of soluble (s) ICAM-1 of around 3 to 5-fold are often found. However, Circulating 
sICAM-1 is shown to block LFA-1; thus promoting tumour growth and angiogenesis7. In contrast, ICAM-1 and/or ICAM-2 negative pancreatic cancer cells are resistant to 
killing by γδ T cells. However, such resistance to killing can be reversed by re-expressing ICAM-1 or ICAM-28. 
Despite the induction of tumour-specific CTL responses by alternative co-stimulation pathways, tumours still develop various strategies to escape anti-tumour immune responses, such as the over-production of prostaglandin (PG) E2 as a result of the up-regulation of the cyclooxygenase-2 (COX-2) gene9,10. PGE2 is a known immune modulator which is able to maintain dendritic cells (DC) in an immature state by: increasing the levels of IL-10 within the tumour microenvironment; enhancing Th17 T cell responses, and recruiting myeloid-derived suppressor cells (MDSC)11. In addition, coupling PGE2 with cognate receptors on T cells can increase cyclic adenosine-monophosphate (cAMP) within T cells which, consequently, reduces T cell proliferation and effector function12. Moreover, PGE2 decreases IFN-γ production by 
T cells. IFN-γ is shown to be involved in enhancing tumour immunogenicity. PGE2 can indirectly affect the expression 
of ICAM-1 by preventing IFN-γ mediated up-regulation of 
ICAM-1. Therefore, we hypothesized that over-expressing ICAM-1 on COX-2-overexpressing Renca-T3 cells would counteract the immunosuppressive effect of PGE2 on 
tumour-specific CD8+ T cells.
To test this hypothesis, and to explore the efficacy of ICAM-1 in providing co-stimulatory signals to tumour-
specific CD8+ T cells, our lab adapted a well-established murine renal carcinoma (Renca) model to generate cells that not only express the haemagglutinin (HA) protein 
from influenza virus A/PR/8/H1N1 (PR8) as a neo-
tumour-specific antigen (Renca-HA;3), but which also over-express COX-2, resulting in the over-production of PGE2 (Renca-T3;12).  
Materials and methods
Mice
6 to 8 wk old Thy1.1+/+ CL4+/- TcR transgenic BALB/c mice (CL4 mice;13) were bred and housed under specific pathogen-free conditions at the University of Bristol Animal Services Unit. All experimental procedures were 
conducted in accordance with U.K. Home Office guidelines.
Murine renal carcinoma (Renca) tumour cells Renca-wild type (WT) were cultured in complete media consisting of RPMI (1640) (Sigma- Aldrich, Poole, UK) 
supplemented with 10 % (v/v) foetal calf serum (FCS), 2 mM L-glutamine, 50 U/ml penicillin/streptomycin (Life technologies, Paisley, UK), 5 ×10-5 M 2-mercapto-ethanol (Sigma-Aldrich, St. Louis, USA). The Renca-HA cells used throughout this study expressed low levels of HA, (Renca-HAlo; as described in3), and were grown in complete medium supplemented with 100 µg/ml geneticin (G418; Sigma-Aldrich), and for Renca-T3 medium was additionally 
supplemented with puromycin (1 μg/mL; Biomatik). Renca-HA/ICAM-1 and Renca-T3/ICAM-1 cells were generated by transfecting tumour cells with 1.5µg of the 
ICAM-1-expressing vector: pIREShyg (a kind gift from Prof. Adrian Whitehouse at Leeds University) and ICAM-1 cDNA (Sino Biological Inc. Beijing, China) by lipofection. All Renca cells were then left to grow in complete media additionally supplemented with 250 µg/ml of hygromycin B. Resistant 
colonies were picked and examined for ICAM-1 expression 
by flowcytometry. Both HA and ICAM-1 expression were 
routinely checked during this study. 
Enrichment and proliferation of CL4 CD8+ T cellsNaïve CL4 CD8+ T cells were purified from peripheral lymphoid tissues isolated from CL4 TcR transgenic mice by magnetic-activated cell sorting (MACS) according to the manufacturer’s instructions (Miltenyi Biotec Ltd., Bisley, UK). In some instances, naïve CL4 T cells were labeled with 5 µM 
carboxyfluorescein succinimidyl ester (CFSE; BioLegend, 
San Diego, USA). MACS-purified CL4 T cell proliferation was detected either; by a 3H-thymidine-based proliferation assay, whereby 1 µCi 3H-thymidine was added in the last 8 hours and the proliferation was measured by thymidine incorporation (counts per minute; cmp) (Amershan Life Science, London, UK), or by a CFSE-based proliferation assay whereby CL4 proliferation was detected by the loss of CFSE 
expression. Naïve CL4 T cells were activated with; 10 μg/ml 
of anti-CD3 mAbs plus either; 5 μg/ml of anti-CD28 mAbs, 
or 3 μg/ml of recombinant (r) ICAM-1, or populations of 
γ-irradiated Renca cells.  Renca cells were irradiated with 9600 RADs using a Cs137 source of γ-irradiation (RX30/55; Gravatom Projects, Grosport, UK).
Flow cytometryActivated CL4 T cells were either left untreated, or stimulated with 1 µg/ml KdHA peptide and 1 µg/ml GolgiPlug (BD Bioscience, San Diego, USA), before 
staining with live/dead aqua and fluorochrome-conjugated monoclonal antibodies (mAbs) for surface staining or they 
were first permeabilized and then stained intracellularly 
for IFN-γ. 
Statistical analysesP values were calculated by one-way ANOVA followed by either Dunnett’s or Bonferroni’s multiple comparison tests using the Prism 5.03 software (GraphPad Software, Inc.). 
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Results
Characterization of ICAM-1 and LFA-1 expression 
by naïve CL4 CD8+ T cellsTo investigate the role of CD8+ T cells in anti-tumour 
immunity, our lab utilized CL4 TcR transgenic mice in which virtually all the CD8+ T cells express the Vα10/Vβ8.2 TcR transgene13. These CL4 T cells are able to recognize the dominant Kd-restricted epitope of the Influenza virus A/PR/8 haemagglutinin (HA) protein (KdHA[IYSTVASSL]) expressed by HA-transfected Renca-HA cells3. Naïve CL4 CD8+ T cells were purified from the total cells harvested from 
lymphoid tissues of CL4 mice using the MACS purification technique. This process routinely results in >98% pure CD8+ T cells (Figure 1A). ICAM-1 has a central role in naïve CD8+ T cell priming3, and acts as a CD28-independent co-stimulator2. ICAM-1 interacts with LFA-1 expressed by T cells which is crucial for homotypic T cell aggregation and communication14. Therefore, MACS-purified naïve CL4 CD8+ T cells were stained for ICAM-1 and LFA-1 expression. 
FACS plots confirm the expression of both ICAM-1 and LFA-1 by naïve CL4 T cells (Figure 1B & C). 
Is ICAM-1 a potent alternative co-stimulatory 
molecule?To evaluate the ability of Renca-HA cells, to prime naïve CL4 CD8+ T cells, both the HA low-expressing Renca-HA cells3, and control Renca-WT cells were used as APC to prime naïve CL4 T cells in a standard 3H-thymidine incorporation T cell proliferation assay. Whilst naïve CL4 T cells did not proliferate in response to control irradiated Renca-WT APCs in vitro, significant levels of CL4 T cell proliferation was observed when cultured with Renca-HA cells as APC (Figure 2A). These data, therefore, suggest that Renca-HA cells are not only able to provide CL4 T cells with signal one but also co-stimulatoty signal two. However, we 
know that although Renca-HA cells lack CD80/CD86; they do express ICAM-1 (Figure 2B). To determine if the co-stimulation in our system occurs 
solely via ICAM-1, anti-ICAM-1 blocking mAbs were added to the CL4 T cells/Renca-HA co-culture. In Figure 3, bar 
charts show that not only does blocking ICAM-1 significantly decrease CL4 T cell proliferation in vitro (A), IFN-γ production is also inhibited; as evidenced by the fact that CL4 T cells were 
unable to produce IFN-γ compared to the non-treated co-culture (Figure 3B: compare 2.7% with 59%). However, the data show that for both CL4 T cell proliferation in response to classical (anti-CD3 mAbs + anti-CD28 mAbs), and alternative (anti-CD3 mAbs + rICAM-1) priming, only the presence of plate-bound rICAM-1 and not soluble (s) rICAM-1 resulted in enhancement of CL4 T cell proliferation. In addition, treating naïve CL4 T cells with rICAM-1 in solution for an hour before 
the beginning of the culture is not sufficient to induce the proliferation to a level similar to that achieved using plate-bound rICAM-1 (Figure 3C). Furthermore, there is a positive correlation between the cell surface expression of ICAM-1 on Renca cells and CL4 T cell proliferation as shown in (Figure 3D & E); the more cell surface ICAM-1 that is expressed the more CL4 T cell proliferation is detected.  Importantly, these differences in proliferation were not due and changes in the level of HA expression, as after overexpressing ICAM-1, HA expression remained the same for all clones; regardless of the levels of ICAM-1 (Figure 3E).
Can ICAM-1 counteract the inhibitory effect of 
PGE2?Although the basal level of ICAM-1 expression by Renca-HA cells is low, such low level expression is enough 
to provide sufficient alternative co-stimulation to prime naïve CL4 CD8+ T cells in vitro. However, despite this, Renca-HA cells continue to grow in vivo. Overexpression of COX-2 by Renca-T3 cells resulted in elevated PGE2 
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Figure 1: TcR, ICAM-1 and LFA-1 expression by naïve CL4 CD8+ T cells. 
A) Spleen and lymph nodes were harvested from CL4 TcR transgenic mice and single cell suspensions were generated. CL4 cells were 
enriched for CD8+ T cells using anti-CD8 magnetic beads and were stained with anti-CD8α-APC and anti-Vβ8-FITC mAbs for flow cytometric 
analyses. The numbers in the top right corner of FACS plot (A) represent the percentage of Vβ8+CD8+ double positive T cells.  MACS-
purified CL4 CD8+ T cells were stained with either (B) anti-CD54-FITC mAbs for ICAM-1, or with (C) anti-CD11a-Alex Fluor 488 mAbs for 
LFA-1. In both (B) and (C), the filled histograms show the isotype control, whereas the solid lines represent the stained cells. Numbers 
represent the mean of fluorescence intensity (MFI). Data are representative of more than 15 separate experiments.
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production; which has been shown to inhibit anti-tumour responses in vitro and in vivo12,15.  To compare the effect of PGE2 on the proliferation and the production of IFN-γ by CD8+ T cells under classical (anti-CD28), and alternative (rICAM-1), co-stimulation pathways, CFSE-labeled CL4 T cells were primed with either; anti-CD3mAbs + anti-CD28 mAbs, or with anti-CD3 mAbs + plate-bound rICAM-1, in the presence or absence of 1 µM PGE2.  In the absence of any PGE2, the FACS plots shown in Figure 4A&B; top row, reveal that around 75% of anti-CD3 mAb-treated CL4 T cells receiving alternative co-stimulation through plate-bound rICAM-1 underwent two or three rounds 
of division; (each peak showing successive loss of CFSE refers to one round of division).  This is compared with only 55% of anti-CD3mAbs-treated CL4 T cells receiving classical costimulatory signaling through anti-CD28 mAbs. This decrease in the proliferation is also associated with 
a reduction in the number of IFN-γ producing CL4 T cells (Figure 4A&B; bottom row).  However, in the presence of PGE2, there is a decrease in IFN-γ-producing CL4 T cells of nearly 4-fold amongst those cells receiving classical anti-CD28 costimulation; compared to a 2-fold decrease in 
IFN-γ production among CL4 T cells receiving alternative costimulation via rICAM-1 (Figure 4A&B; bottom row).
Figure 2: CL4 CD8+ T cell proliferation in response to Renca-WT or Renca-HA cells.
A) MACS-purified naïve CL4 CD8+ T cells were co-cultured with either irradiated Renca-WT or Renca-HA cells as APCs at a 1:1 effector:target 
ratio, for 48 and 72 hours. Plates were pulsed with 1 µCi of 3H-thymidine in the last 8 hours. After which, CL4 T cells were harvested 
and the level of 3H-thymidine incorporation was measured. Bar charts show counts per minute (cpm). Error bars represent mean 
±SEM. Data are representative of 3 separate experiments. Statistical analyses were carried out using one-way ANOVA followed by 
Dunnett’s multiple compression test. ** P<0.01
B) Renca-WT and Renca-HA cells were harvested and stained with live/dead aqua and fluorochrome-conjugated mAbs: anti-CD80-FITC, 
anti-CD86-Alex Fluor 647, anti-CD54-FITC and anti-CD11a -Alex Fluor 488.  HA expression was examined using 2-step FACS staining in 
which Renca cells were incubated first with anti-HA-biotin (Bio), followed by Streptavidin (SA)-PE. Filled lines represent the isotype 
control, whereas the dotted lines show the indicated surface molecule. Numbers represent the mean of fluorescence intensity (MFI). 
Data are representative of 3 separate experiments.
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Figure 3: Proliferation and IFN-γ production by CL4 CD8+ T cells in the presence or absence of anti-ICAM-1 blocking mAbs. 
(A) MACS-purified naïve CL4 CD8+ T cells were co-cultured for with irradiated Renca-HA at a 1:1 effector: target ratio in the absence or presence of 10 µg/ml 
goat anti-mouse ICAM-1/CD54 antibody, or with goat IgG isotype control. During the final 8 hours, cultures were pulsed with 1 µCi 3H-thymidine.  CL4 cells 
were harvested and analysed for 3H-thymidine incorporation. Bar charts show counts per minute (cmp). Error bars are mean ±SEM. Data are representative 
of 3 separate experiments. Statistical analyses were carried out using one way ANOVA followed by Dunnett’s multiple comparison test. ** P<0.01. 
(B) 1x106 MACS-purified naïve CL4 CD8+ T cells were co-labelled with CFSE and cultured with 1x105 irradiated Renca-HA cells in the absence or presence of 
10 µg/ml goat anti-mouse ICAM-1 blocking mAbs, or with goat IgG isotype control mABs, for 72 hours.  CL4 T cells were then collected re-stimulated with 
1 µg/ml of KdHA and Golgi plug for four hours, and then stained with live/dead aqua before being permeabilized and stained intracellularly with anti-IFN-
γ-APC mAbs. FACS plots show the expression of CFSE versus the production of IFN-γ by CL4 T cells. The numbers in each FACS plot show the percentage of 
proliferated CL4 T cells that are also IFN-γ-positive (top left corner). Data are representative of 3 separate experiments. 
(C) 1x104 MACS-purified naïve CL4 CD8+ T cells were primed with plate-bound anti-CD3 mAbs (10 µg/ml) alone, or in a combination with either anti-CD28 
mAbs (5 µg/ml) or plate-bound or soluble rICAM-1 (3 µg/ml).  A proportion of CL4 T cells were pre-treated with rICAM-1 for an hour before the unbound 
ICAM-1 antibodies were washed, for 48 and 72 hours. Plates were pulsed with 1 µCi 3H-thymidine in the last 8 hours. Bar charts show counts per minute 
(cpm). Error bars are mean ±SEM. Data are representative of 4 separate experiments. Statistical analyses were carried out using one way ANOVA followed 
by Bonferroni multiple comparison test.  ** P< 0.01,* P˂ 0.05. 
(D) MACS-purified CL4 CD8+ T cells were co-cultured for 48 and 72 hours with irradiated Renca-HA, Renca-HA/vector and various Renca-HA/ICAM-1 cells 
expressing relatively high, intermediate & low levels of ICAM-1. During the last 8 hours of each culture cells were pulsed with 1 µCi of 3H-thymidine. Bar 
charts show counts per minute (cpm), error bars show mean ±SEM. and all data are representative of 2 separate experiments. 
(E) Renca-HA/vector and Renca-HA/ICAM-1 cells that express high, intermediate and low levels of ICAM-1 were harvested and stained with live/dead aqua, 
HA-biotin (Bio) followed by SA-PE mAbs (left column) and anti-CD54-FITC mAbs (right column). Red filled histograms show the isotype control, whereas the 
blue histograms represent the HA-stained or ICAM-1-stained cells.
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Figure 4: Proliferation and IFN-γ production by CL4 CD8+ T cells in the presence or absence of PGE2.
1x106 CFSE-labelled MACS-purified naïve CL4 CD8+ T cells were cultured with anti-CD3 mAbs (10 µg/ml), plus either anti-CD28 mAbs (5 
µg/ml) (A), or plate-bound rICAM-1 (3 µg/ml) (B) in the presence or the absence of 1 µM PGE
2
 for 48 hours. CL4 T cells were collected 
from the culture and re-stimulated with 1 µg/ml of both KdHA and Golgi plug and incubated for a further four hours, and then stained 
with live/dead aqua dye before being permeabilized and stained intracellularly with anti-IFN-γ-APC mAbs. All Samples were analysed by 
flow cytometer. Dot plots are gated on live CFSE-labelled cells. FACS plots show the expression of CFSE versus; counts (top rows), or the 
expression of IFN-γ (bottom rows). Numbers in the top left corner of each plot show the percentage of positive proliferated cells for IFN-γ. 
Data are representative of 4 separate experiments.It has been shown that some molecules such as matrix metalloproteinase 9 (MMP-9) can cause ICAM-1 to be shed from the surface of tumour cells and is involved in tumour evasion from the immune surveillance. ICAM-1 provides 
a docking site for pro-MMP-9 which proteolytically cleaves the extracellular domain of ICAM-1 leading to its release from the cell surface16.  To determine whether or not PGE2 directly affect the priming of naïve CL4 cells by causing ICAM-1 to be shed from the surface of tumour cells, Renca-HA cells were cultured in the presence of 1µM PGE2 for 72 hours then stained for HA and ICAM-1 expression.  Data presented in Figure 5A show that Renca-HA cells maintained the same levels of both HA and ICAM-1 following PGE2 treatment suggesting that PGE2 does not cause modulation or shedding of these molecules from the cell surface.
IFN-γ is able to exert its anti-tumour effects by directly acting upon the tumour cells themselves17; as evidenced by 
the fact that tumour cells lacking IFN-γR expression grow in mice despite the presence of effective anti-tumour immune 
responses, which would otherwise kill IFN-γR-sufficient tumour cells18.  One mechanism through which IFN-γ is thought to reduce the growth of tumour cells in vivo is by 
enhancing tumour cell immunogenicity19.  Indeed, IFN-γ has been shown to increase antigen presentation to CD8+ T cells by increasing MHC class I and ICAM-1 expression by tumour cells3.  Similarly, IFN-γ treatment of Renca-HA cells 
also resulted in a marked increase in ICAM-1 expression (Figure 5B).To determine whether or not the up-regulation of ICAM-1 is instrumental in abrogating the effect of PGE2, we generated an ICAM-1 overexpressing Renca-T3 cell line (Renca-T3/ICAM-1), for co-culture with CFSE-labeled naïve CL4 T cells in vitro.  The data show that co-culture with this 
cell line resulted in a significant increase in proliferation of CFSE-labelled naïve CL4 T cells, whereby greater than 65% of cells undergo at least three rounds of divisions compared with around 18% of CL4 T cells co-cultured in the presence of either un-transfected Renca-T3 or Renca-T3 empty-vector control cells (Figure 5C; top row). Moreover, co-culture with Renca-T3/ICAM-1 also resulted in a large increase in CTL effector function as evidence 
by the fact that around 60% of CL4 cells expressed IFN-γ, compared with only 18% of CL4 cells that were co-cultured in the presence of control Renca-T3 or Renca-T3 empty-
vector cells (Figure 5C; bottom row). Taken together, these 
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Figure 5: The correlation between IFN-γ, ICAM-1 and PGE2 in CL4 CD8
+ T cell response
A) Renca-HA cells were treated with 1 µM exogenous PGE
2
 for 72 hours. Renca tumour cells were collected and stained with live/
dead aqua, HA-bio followed by SA-PE mAbs and anti-CD54-FITC mAbs. Filled red histograms show the isotype control, whereas the 
dotted blue lines represent PGE
2
-non-treated culture and grey line histograms show PGE
2
-treated culture. Data are representative of 
4 separate experiments.
B) Renca-HA cells were cultured in the presence or absence of 10 ng/ml IFN-γ for 48 hours. Renca cells were collected and stained with 
anti-CD54-FITC mAbs and isotype control. Filled lines represent isotype control, whereas solid lines show IFN-γ-non-treated culture, 
and dashed lines show IFN-γ- treated cells. 
C) CFSE-labelled MACS-purified naïve CL4 CD8+ T cells were co-cultured with irradiated Renca-T3 and Renca-T3/vector and Renca-T3/
ICAM-1 cells for 48 hours. CL4 T cells were collected and re-stimulated with 1 µg/ml of KdHA and Golgi plug. CL4 T cells were then 
stained with live/dead aqua before being permeabilized and stained with anti-IFN-γ-APC mAbs. FACS plots show the expression 
of CFSE versus the production of IFN-γ (bottom row), and counts (top row). Numbers in each FACS plot show the percentage of 
proliferated CL4 T cells that are IFN-γ-positives (top left corner). Data are representative of 3 separate experiments.
DiscussionThe requirement of ICAM-1-mediated co-stimulation in T cell priming has remained controversial. Some data clearly demonstrate that overexpression of ICAM-1 by RencaT3/ICAM-1 cells is able to circumvent the PGE 2-mediated suppression of tumour-specific CTL responses. 
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reports suggest that ICAM-1 is not sufficient for CD4+ T cell activation. In contrast, other reports propose the essential need of ICAM-1 for T cell priming but not for 
cytokine secretion, whereas others suggest that ICAM-
1 can stimulate both activation and cytokine secretion20. 
However, studies using ICAM-1 knockout mice suggests that ICAM-1 is not essential in T cell-mediated tumour rejection 
if sufficient numbers of T cells are transferred21. In our 
study, Renca-HA tumour cells, that lack expression of both CD80/CD86, provide KdHA-specific CL4 CD8+ T cells with 
sufficient co-stimulation through ICAM-1 interactions with T cell-expressed LFA-1 that not only results in proliferation 
but also in IFN-γ production. This was evidenced by the 
clear finding that the presence of both anti-ICAM-1 and 
anti-LFA-1 mAbs during priming significantly reduces CL4 
T cell proliferation and IFN-γ production3. Although the interaction of LFA-1 on T cells with soluble or plate-bound rICAM-1 can prime naive CD8+ T cells, only plate-bound 
rICAM-1 enhances markedly the CL4 T cell response.  This 
finding is consistent with a study in which T cells from 
mice lacking full-length cell-surface expression of either 
cell surface ICAM-1 or LFA-1 had significantly impaired T cell function22.  It also supports the findings from another 
study in which over-expression of soluble rICAM-1 blocked LFA-1 on T cells preventing subsequent T cell activation due to the inability of LFA-1 to bind cell-surface ICAM-1. We have shown that overexpressing cell surface ICAM-1 on Renca-HA cells increased CL4 T cell proliferation and 
IFN-γ. This finding correlates with other studies in which the up-regulation of ICAM-1 on melanoma cells induced by retinoic acid, or ICAM-1 gene transfection, was found to improve the susceptibility of melanoma cells to lysis by 
lymphokine activated killer cells (LAK)23. Nevertheless, Renca-HA tumour cells continue to grow in vivo when they are injected into BALB/c mice either alone, or with large 
numbers of naïve CL4 cells. (CN Janicki and DJ Morgan; unpublished data).  Following adoptive transfer, CL4 T cells undergo productive activation within the TDLNs, but they lose their effector function once they reach to the tumour site due to the immunosuppression created within the tumour microenvironment24. Many solid tumours create an immunosuppressive microenvironment through various immune escape strategies such as the production of PGE2. Over-expression of COX-2 not only results in high levels of PGE2 production, but also tumour cell metastasis by Renca-T3 cells and suppression of activation of naive CL4 CD8+ T cells.  Such abortive activation is evidenced by 
lack of proliferation and the absence of IFN-γ production due to the maintenance of low level ICAM-1 expression12. 
Whereas, exposure to IFN-γ was shown to markedly up-
regulate ICAM-1. These findings correlate with other 
studies, which suggest that IFN-γ enhances antigen presentation by tumour cells through the increase of MHC class I expression18. We showed that disabling PGE2 production by COX-2 inhibitor has shown to restore 
IFN-γ production by effector T cells25. Significantly, over expression of ICAM-1 on Renca-T3 cells restores CL4 T 
cell proliferation as well as IFN-γ production even in the PGE2-rich microenvironment. Our findings clearly show that PGE2 is able to inhibit both the direct priming of naïve 
tumour-specific CD8+ T cells, as well as the effector function 
amongst a tumour-specific CTL, this effect is temporary and may be mitigated by increasing ICAM-1 expression on tumour cells which therefore enable the ligation of LFA-1 on CL4 with ICAM-1 on tumour cell which then allows the formation of a stable synapse between the two cell types and prolongs this interaction. Along with LFA-1/ICAM-1 binding, the interactions of TcR with KdHA further increase Ca2+ influx and maintain LFA-1 in a high affinity state.  In this state, the inhibitory effects, induced by PGE2-mediated up-regulation of cAMP levels, on Ca2+ influx within CL4 T cells fail to override the stimulatory signals through stable LFA-1/ICAM-1 and TcR/KdHA interactions. As a result, 
tumour-specific CD8+ T cells are forced to proliferate more 
and produce high levels of IFN-γ and therefore may have greater potential to prevent tumour growth in vivo. These 
findings clearly indicate that drugs which can increase the cell-surface expression of ICAM-1 by tumor cells could provide us with a powerful immune-therapeutic tool to counteract the immunosuppressive action of tumor-derived PGE2 to greatly enhance anti-tumor CTL responses, which may ultimately control tumor growth.
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